Hum. Reprod. Advance Access published online on June 24, 2004
Human Reproduction, doi:10.1093/humrep/deh373
© 2004 by European Society of Human Reproduction and Embryology
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Reproductive Medicine, Department of Obstetrics and Gynecology, The Netherlands
* To whom correspondence should be addressed. E-mail: j.laven{at}erasmusmc.nl.
BACKGROUND: Anti-Müllerian hormone (AMH), produced by growing pre-antral and early antral ovarian follicles, has been shown to be a useful marker for ovarian ageing. Serum AMH concentrations are elevated during reproductive life in anovulatory women, especially in those patients exhibiting polycystic ovaries (PCO). The current study was designed to investigate whether the decrease in AMH serum concentrations over time is different comparing women with normogonadotrophic anovulation [World Health Organization (WHO) group 2 (including polycystic ovary syndrome (PCOS)] and normo-ovulatory controls. METHODS and RESULTS: AMH serum levels were assessed on two occasions in 98 patients suffering from WHO 2 anovulatory infertility as well as in 41 normo-ovulatory premenopausal women. Median time interval between both visits was 2.6 years (range 0.3-9.0) for WHO 2 patients compared with 1.6 years (range 1.0-7.3) in controls. Serum AMH concentrations were significantly (P<0.0001) elevated on both occasions in WHO 2 patients (AMH1, median = 7.5 µg/l, range 0.1-35.8; and AMH2, median = 6.7 µg/l, range 0.0-30.6) compared with controls (AMH1, median = 2.1 µg/l, range 0.1-7.4; and AMH2, median = 1.3 µg/l, range 0.0-5.0). Regression analysis, corrected for age, indicated a significant relative decrease in serum AMH concentrations over time for both groups (P<0.001). However, the decline in serum AMH in WHO 2 patients was significantly less compared with controls (P=0.03). CONCLUSION: The present longitudinal study shows that serum AMH concentrations decrease over time both in women presenting with WHO 2 anovulatory infertility and in normo-ovulatory controls. The decrease in WHO 2 patients is less pronounced despite distinctly elevated concentrations. This observation may suggest retarded ovarian ageing and hence a sustained reproductive life span in these patients.
Accepted May 25, 2004
Article
Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility
2 Center for Clinical Decision Sciences, Department of Public Health, The Netherlands
3 Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
4 Division of Reproductive Medicine, Department of Obstetrics and Gynecology, The Netherlands; Department of Reproductive Medicine, University Medical Center, Utrecht, The Netherlands
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. L Walker, D. C Anderson, J. G Herndon, and L. C Walker Ovarian aging in squirrel monkeys (Saimiri sciureus) Reproduction, November 1, 2009; 138(5): 793 - 799. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Nardo, A. P. Yates, S. A. Roberts, P. Pemberton, and I. Laing The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome Hum. Reprod., November 1, 2009; 24(11): 2917 - 2923. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. La Marca, G. Sighinolfi, D. Radi, C. Argento, E. Baraldi, A. C. Artenisio, G. Stabile, and A. Volpe Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART) Hum. Reprod. Update, September 30, 2009; (2009) dmp036v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. La Marca, F.J. Broekmans, A. Volpe, B.C. Fauser, N.S. Macklon, and on behalf of the ESHRE Special Interest Group for Anti-Mullerian hormone (AMH): what do we still need to know? Hum. Reprod., September 1, 2009; 24(9): 2264 - 2275. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rico, S. Fabre, C. Medigue, N. d. Clemente, F. Clement, M. Bontoux, J.-L. Touze, M. Dupont, E. Briant, B. Remy, et al. Anti-Mullerian Hormone Is an Endocrine Marker of Ovarian Gonadotropin-Responsive Follicles and Can Help to Predict Superovulatory Responses in the Cow Biol Reprod, January 1, 2009; 80(1): 50 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Maheshwari, P. Fowler, and S. Bhattacharya Assessment of ovarian reserve--should we perform tests of ovarian reserve routinely? Hum. Reprod., November 1, 2006; 21(11): 2729 - 2735. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A Visser, F. H de Jong, J. S E Laven, and A. P N Themmen Anti-Mullerian hormone: a new marker for ovarian function Reproduction, January 1, 2006; 131(1): 1 - 9. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Stubbs, K. Hardy, P. Da Silva-Buttkus, J. Stark, L. J. Webber, A. M. Flanagan, A. P. N. Themmen, J. A. Visser, N. P. Groome, and S. Franks Anti-Mullerian Hormone Protein Expression Is Reduced during the Initial Stages of Follicle Development in Human Polycystic Ovaries J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5536 - 5543. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Piltonen, L. Morin-Papunen, R. Koivunen, A. Perheentupa, A. Ruokonen, and J. S. Tapanainen Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome Hum. Reprod., July 1, 2005; 20(7): 1820 - 1826. [Abstract] [Full Text] [PDF] |
||||




